Clinical Trials
15 trialsNCT07544654 2026-05-27
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Not yet recruiting
NCT00569127 2026-05-26
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04940052 2026-05-22
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
Novartis
Phase 3 Active not recruiting
NCT03194893 2026-05-20
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05884255 2026-05-19
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT07595913 2026-05-19
A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Not yet recruiting
NCT06881992 2026-05-18
Tumor HI
Rezolute
Phase 3 Recruiting
NCT07591493 2026-05-15
ADJUPANET
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Not yet recruiting
NCT05918302 2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3 Recruiting
NCT03375320 2026-05-01
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06784752 2026-04-30
NETTER-3
Novartis
Phase 3 Recruiting
NCT07087054 2026-04-30
CAREFNDR
Crinetics Pharmaceuticals Inc.
Phase 3 Recruiting
NCT03049189 2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3 Active not recruiting
NCT05477576 2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT04810091 2026-03-09
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
M.D. Anderson Cancer Center
Phase 3 Active not recruiting